


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on May 6, 2010.



Frank C. Eisenschenk, Ph.D., Patent Attorney

STATEMENT OF SUBSTANCE OF
INTERVIEW
Patent Application
Docket No. SER.108C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Examiner : Padmavathi V. Baskar
Art Unit : 1645
Applicants : Beat A. Imhof, Michel Aurrand-Lions
Serial No. : 10/579,105
Filed : February 6, 2007
Confirm. No. : 3550
For : Angiogenesis Inhibiting Molecules and Their Use in the Treatment and
Diagnosis of Cancer

MS ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 C.F.R. §1.133

The applicants wish to thank Examiner Baskar for the courtesy of the telephonic examiner interview conducted on April 19, 2010 with the undersigned. The remarks set forth in the Interview Summary Form that accompanied the Notice of Allowability dated May 5, 2010 are consistent with the substance of that interview and are believed to address the outstanding issues as discussed during the interview. Permission was granted by the undersigned during the interview to amend claim 29.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
P.O. Box 142950
Gainesville, FL 32614-2950

FCE/jb